ACH on NYSE

Owens & Minor

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons5

Healthcare logistics company

Accendra Health is a global healthcare company. It employs over 20,000 people in 70 countries. A Fortune 500 company, it was founded in 1882 in Richmond, Virginia, where it remains headquartered.3 Its shares trade on NYSE under the symbol ACH.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1882Founded1

Compare with Patterson Companies, Henry Schein or Teladoc, or pick any stock.

  • TickerACH on NYSE1
  • Industryhealth care1
  • HeadquartersMechanicsville1
  • Websiteowens-minor.com
  • Incorporated inVA6
  • Business address4435 Waterfront Drive, Suite 300, Glen Allen, Va6
  • Filer categoryLarge accelerated filer6
  • Legal formStock Corporation4
  • LEI549300LMT5KQQXCEZ7334
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O C T CORPORATION SYSTEM, 23060 Glen Allen, United States4
  • Registered withState Corporation Commission, 041976614

Accendra Health is a global healthcare company. It employs over 20,000 people in 70 countries. A Fortune 500 company, it was founded in 1882 in Richmond, Virginia, where it remains headquartered. The company has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. President and CEO Ed Pesicka joined Owens & Minor in March 2019.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

1.0%Operating margin8
-39.8%Net margin8
3.1%Revenue growth, 20258

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Diabetes Product brought in 28% of the revenue Owens & Minor broke down this way in fiscal 2025.

  1. Diabetes Product$783.4M828%up 1% from 2024
  2. Sleep Therapy Product$740.1M827%up 5% from 2024
  3. Home Respiratory Therapy Product$433.1M816%down 1% from 2024
  4. Product and Service, Other$288.2M810%up 7% from 2024
  5. Ostomy$212.8M88%up 9% from 2024
  6. Wound Care$188.5M87%down 2% from 2024
  7. Urology$116.0M84%up 8% from 2024
Products and services by year
Products and services202320242025
Diabetes Product$723.3M$777.5M$783.4M
Sleep Therapy Product$669.8M$703.0M$740.1M
Home Respiratory Therapy Product$457.7M$436.0M$433.1M
Product and Service, Other$255.0M$268.3M$288.2M
Ostomy$177.9M$195.9M$212.8M
Wound Care$170.9M$192.4M$188.5M
Urology$98.0M$107.1M$116.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue53¢$1.5B
  • Selling, general and admin39¢$1.1B
  • Other costs4¢$113.8M
  • Interest4¢$107.2M
  • Income tax0¢$729.0K

Out of $2.8B in revenue.8 The company lost money this year.

Financial statements

Revenue91011128$2.8B in 2025−70% since 2019
0$2.5B$5.0B$7.5B$10.0B2019: $9.2B$9.2B20192020: $8.5B$8.5B2020−8%2021: $9.8B$9.8B2021+15%2022: $10.0B$10.0B2022+2%2023: $2.6B$2.6B2023−74%2024: $2.7B$2.7B2024+5%2025: $2.8B$2.8B2025+3%
Gross profit9101112$2.2B in 2024+97% since 2019
0$1.0B$2.0B$3.0B2019: $1.1B$1.1B20192020: $1.3B$1.3B2020+13%2021: $1.5B$1.5B2021+18%2022: $1.8B$1.8B2022+21%2023: $2.1B$2.1B2023+16%2024: $2.2B$2.2B2024+4%
Operating income91011128$27.5M in 2025−62% since 2019
-$400.0M-$200.0M0$200.0M$400.0M2019: $73.2M$73.2M20192020: $204.1M$204.1M2020+179%2021: $368.5M$368.5M2021+81%2022: $142.9M$142.9M2022−61%2023: $133.2M$133.2M2023−7%2024: -$217.7M-$217.7M20242025: $27.5M$27.5M2025
Net income91011128-$1.1B in 2025+1665% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$62.4M-$62.4M20192020: $29.9M$29.9M20202021: $221.6M$221.6M2021+642%2022: $22.4M$22.4M2022−90%2023: -$41.3M-$41.3M20232024: -$362.7M-$362.7M2024+778%2025: -$1.1B-$1.1B2025+203%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Net revenue$2.8B$2.7B$2.6B
Cost of net revenue$1.5B$1.4B$1.3B
Selling, general and administrative expenses$1.1B$1.1B$1.0B
Goodwill impairment charge$0$307.1M
Transaction breakage fee$80.0M
Acquisition-related charges and intangible amortization$95.8M$61.8M$74.8M
Exit and realignment charges, net$18.4M$46.8M$7.3M
Total operating costs and expenses$2.7B$2.9B$2.4B
Operating income (loss)$27.5M-$217.7M$133.2M
Interest expense, net$107.2M$107.6M$116.8M
Transaction financing fees, net$18.3M$0$0
Other expense, net$3.9M$4.6M$1.2M
(Loss) income from continuing operations before income taxes-$102.0M-$329.9M$15.3M
Income tax provision$729.0K$20.9M$6.4M
(Loss) income from continuing operations, net of tax-$102.7M-$350.7M$8.9M
Loss from discontinued operations, net of tax$998.0M$12.0M$50.2M
Net loss-$1.1B-$362.7M-$41.3M
(Loss) income from continuing operations, net of tax (in dollars per share)-$1-$5$0
Loss from discontinued operations, net of tax (in dollars per share)-$13-$0-$1
Net loss per common share Basic (in dollars per share)-$14.31-$4.73-$0.54
(Loss) income from continuing operations, net of tax (in dollars per share)-$1-$5$0
Loss from discontinued operations, net of tax (in dollars per share)-$13-$0-$1
Net loss per common share Diluted (in dollars per share)-$14.31-$4.73-$0.53

Compare Owens & Minor with another company

Corporate structure

Owens & Minor sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Owens & Minor

  • Bank of America Filed SCHEDULE 13G on Owens & Minor, latest Oct 7, 2026
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC Filed SCHEDULE 13G/A on Owens & Minor, latest May 14, 2026 (2 filings since Feb 12, 2026)
  • Kevin Michael Webb Filed SCHEDULE 13G on Owens & Minor, latest Mar 30, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Owens & Minor, latest Mar 26, 2026 (5 filings since Feb 10, 2022)
  • Coliseum Capital Management, LLC Filed SCHEDULE 13D on Owens & Minor, latest Nov 14, 2025 (4 filings since Dec 27, 2024)
  • DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on Owens & Minor, latest Oct 9, 2025 (3 filings since Feb 8, 2022)
  • BlackRock Filed SCHEDULE 13G/A on Owens & Minor, latest Oct 2, 2025 (6 filings since Jan 25, 2022)
  • James E. Flynn Filed SCHEDULE 13G/A on Owens & Minor, latest May 13, 2025 (3 filings since Apr 6, 2023)
  • FMR LLC Filed SCHEDULE 13G/A on Owens & Minor, latest May 12, 2025 (6 filings since Mar 10, 2022)
  • Wellington Management Company Filed SC 13G/A on Owens & Minor, latest Nov 9, 2023 (5 filings since Oct 8, 2021)
  • Owens & Minor Mechanicsville, Virginia, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Owens & Minor reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$463.8M8 Dec 31, 2025$433.0M8 Dec 31, 2024+7.1%
Accumulated depreciation$207.6M8 Dec 31, 2025$183.7M8 Dec 31, 2024+13.0%
Property and equipment, net$256.2M8 Dec 31, 2025$249.3M8 Dec 31, 2024+2.8%
Finance-lease assets$6.4M12 Dec 31, 2024$8.5M12 Dec 31, 2023−24.8%
Operating-lease assets (leased space)$109.1M8 Dec 31, 2025$126.9M8 Dec 31, 2024−14.0%

Real estate and locations

ItemLatestA year beforeChange
Countries it operates in8012 Dec 31, 20248011 Dec 31, 20230%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$282.0M8 Dec 31, 2025$27.6M8 Dec 31, 2024+922.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.2B8 Dec 31, 2025$1.2B8 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$136.5M8 Dec 31, 2025$210.1M8 Dec 31, 2024−35.0%
Finite-lived intangibles, net$136.5M8 Dec 31, 2025$296.7M12 Dec 31, 2024−54.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$74.4M8 Dec 31, 2025$67.6M8 Dec 31, 2024+10.1%
Raw materials$77.9M12 Dec 31, 2024$75.7M12 Dec 31, 2023+2.9%
Work in process$59.1M12 Dec 31, 2024$61.5M12 Dec 31, 2023−3.9%
Finished goods$1.1B12 Dec 31, 2024$1.1B12 Dec 31, 2023+0.8%

Properties, in its own words

As of December 31, 2025, following the P&HS Sale, we had over 250 locations to serve patients across the U.S., centers of excellence aligned with specific mail order product categories, as well as regional distribution and repair centers, customer service and billing centers, a national pharmacy and a biomedical center for the repair, maintenance and distribution of patient service equipment.

We regularly assess our business needs and make changes to the capacity and the location of our facilities. We believe that our facilities are adequate to carry on our business as currently conducted. A number of leases are scheduled to expire within the next several years. We believe that, if necessary, we could find facilities to replace these leased premises without suffering a material adverse effect on our business. For information on material lease commitments see Note 6, “Leases”, in the Notes to Consolidated Financial Statements.

Item 2 of the 10-K filed Feb 20, 2026.17

The story

Owens & Minor originally opened as a pharmacy company in downtown Richmond, Virginia in 1882, inside a historic building which still stands today. The company continued this business for over half a century until, in 1954, Gil Minor, Jr. bought out Bodeker Drug Company, a smaller operation in the same industry, changing the company name to Owens, Minor & Bodeker.

In 1966, the company acquired Virginia A&J Hospital Supply, adding medical and surgical distribution to its portfolio. By 1970, OMB had opened Cardinal Drug Centers, merchandising its products to independent drug companies, stocking shops with over 25,000 items within two years. Around this time, disposable items were distributed to hospitals for various medical procedures. G. Gilmer Minor III, a direct relation to the founder, became CEO in 1984. By 1988, Owens & Minor began trading on the New York Stock Exchange under the ticker OMI. It was around this time that revenues earned the company a Fortune 500 ranking.

By 1999, the company had refocused toward medical supply chain management. Throughout the 2000s, Owens & Minor acquired various medical distributors across the United States, notably the hospital distributor McKesson Medical-Surgical Inc., a business unit of McKesson, for $152.1 million, on September 30, 2006. In 2012, it entered the European market, opening offices in Spain, France, Germany, Poland, and the Czech Republic after the acquisition of Movianto Group. In 2014, the corporation acquired ArcRoyal, a privately held medical kit company based in Dublin, Ireland.

In 2018, it acquired Halyard Health’s Surgical & Infection Prevention business for $710 million, the largest acquisition in the company’s history. Halyard is a manufacturer of sterilization wrap, facial protection products, exam gloves, protective apparel, surgical drapes and surgical gowns.

In May 2022, Owens & Minor stated that 45 percent of the items it offers are in some way supply-constrained due to the 2021–2022 global supply chain crisis. The following month, the company broke ground in Morgantown, West Virginia for a 350,000 square-foot medical supplies and logistics center, to be completed in late 2023, which will include dedicated acute care medical distribution facilities and clinical supply capabilities.

In July 2024, the company announced it had agreed to acquire medical equipment firm Rotech Healthcare for $1.36 billion. However, the companies terminated the deal in June 2025, citing regulatory hurtles. As a result, the Owens & Minor paid Rotech an $80 million termination payment.

From Wikipedia’s article on Accendra Health, shared under CC BY-SA 4.0.7

Leadership

Who has led Owens & Minor, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (74)

Products and brands

On December 31 2025, Owens & Minor, Inc. announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc.

From Wikipedia’s article on Accendra Health, shared under CC BY-SA 4.0.7

Former names

  • OWENS & MINOR INC/VA/Aug 10, 1994 to Dec 31, 20256
  • O&M HOLDING INCJun 17, 1994 to Jun 17, 19946
  • OWENS & MINOR INCApr 22, 1994 to Mar 9, 19946

Timeline

  1. Oct 9, 20268-K Listing notice or transfer; Regulation FD disclosure111
  2. Oct 6, 2026New chief executive Kenneth Gardner-Smith becomes CEO18
  3. Sep 28, 20268-K Executive or director change112
  4. Sep 17, 20268-K Executive or director change; Regulation FD disclosure; Other events113
  5. Aug 17, 20268-K Regulation FD disclosure114
  6. Aug 10, 20268-K Executive or director change; Regulation FD disclosure115
  7. Aug 10, 20268-K Results of operations; Regulation FD disclosure116
  8. Aug 10, 20268-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed117
  9. Jun 25, 20268-K Other events118
  10. Jun 15, 20268-K Entered a material agreement; New debt or obligation; Other events119
  11. May 22, 20268-K Regulation FD disclosure120
  12. May 15, 20268-K Executive or director change; Shareholder vote121
  13. May 11, 20268-K Results of operations; Regulation FD disclosure122
  14. Mar 2, 2023New chief executive Perry A. Bernocchi becomes CEO19
  15. Nov 14, 2022New chief executive Andrew G. Long becomes CEO20
  16. Mar 7, 2019New chief executive Edward A. Pesicka becomes CEO21
  17. Nov 8, 2018New chief executive Robert Sledd becomes CEO22
  18. Jul 1, 2015New chief executive Paul Cody Phipps becomes CEO23
  19. Sep 3, 2014New chief executive James L. Bierman becomes CEO24
  20. Aug 13, 2003New chief executive G. Gilmer Minor Iii. becomes CEO25
  21. 1882Founded Founded1

Calendar

Coming up

  1. Oct 29, 2026Reports results for the quarter ending Sep/2026123

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results116
  2. May 11, 2026Reported quarterly or annual results122
  3. Feb 19, 2026Reported quarterly or annual results124
  4. Oct 30, 2025Reported quarterly or annual results125
  5. Aug 11, 2025Reported quarterly or annual results126
  6. May 8, 2025Reported quarterly or annual results127
  7. Feb 28, 2025Reported quarterly or annual results128
  8. Feb 3, 2025Reported quarterly or annual results129

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

471 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 85 major events, 267 insider forms, 36 large holders, 63 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Oct 7, 2026SCHEDULE 13G EDGAR
  3. Oct 6, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  4. Sep 28, 20268-K/A EDGAR
  5. Sep 24, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  6. Sep 17, 20268-K EDGAR
  7. Sep 11, 2026144 EDGAR
  8. Aug 17, 20268-K EDGAR
  9. Aug 10, 20268-A12B EDGAR
  10. Aug 10, 20268-K EDGAR
  11. Aug 10, 202610-Q EDGAR
  12. Aug 10, 20268-K EDGAR
  13. Aug 10, 20268-K EDGAR
  14. Jul 24, 2026EFFECT EDGAR
  15. Jul 15, 2026S-3 EDGAR
  16. Jun 25, 20268-K EDGAR
  17. Jun 15, 20268-K EDGAR
  18. May 29, 2026SD EDGAR
  19. May 22, 20268-K EDGAR
  20. May 20, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 471 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

54 open-market trades by officers, directors and large owners since October 2021: 16 buys and 38 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 14, 2025Coliseum Capital Management, LLC10% ownerBuy492,852$5.31$2.6MForm 4
Aug 13, 2025Coliseum Capital Management, LLC10% ownerBuy325,000$5.46$1.8MForm 4
Aug 12, 2025Coliseum Capital Management, LLC10% ownerBuy720,000$5.15$3.7MForm 4
Apr 10, 2025Coliseum Capital Management, LLC10% ownerBuy80,000$7.19$575.2KForm 4
Apr 9, 2025Coliseum Capital Management, LLC10% ownerBuy225,000$7.39$1.7MForm 4
Apr 8, 2025Coliseum Capital Management, LLC10% ownerBuy105,000$7.96$835.8KForm 4
Apr 7, 2025Coliseum Capital Management, LLC10% ownerBuy240,000$7.84$1.9MForm 4
Apr 4, 2025Coliseum Capital Management, LLC10% ownerBuy128,356$8.14$1.0MForm 4
Apr 3, 2025Coliseum Capital Management, LLC10% ownerBuy160,000$8.53$1.4MForm 4
Mar 4, 2025Coliseum Capital Management, LLC10% ownerBuy800,000$9.75$7.8MForm 4
Mar 3, 2025Coliseum Capital Management, LLC10% ownerBuy354,901$9.19$3.3MForm 4
Feb 28, 2025Coliseum Capital Management, LLC10% ownerBuy1,738,511$9.39$16.3MForm 4
Nov 21, 2024Leon Jonathan AEVP & CFOSale5,282$11.82$62.4KForm 4
Nov 18, 2024Sarkar SnehashishSale2,055$12.26$25.2KForm 4
Aug 22, 2024Leon Jonathan AEVP & CFOSale7,500$15.83$118.7KForm 4
Jun 6, 2024Bernocchi Perry AEVP, Chief Operating OfficerSale20,015$17.49$350.0KForm 4
Jun 5, 2024Beck Mark ADirectorSale9,344$17.25$161.2KForm 4
Jun 4, 2024Sarkar SnehashishSale9,980$17.32$172.9KForm 4
Jun 3, 2024Bruni Alexander JEVP, CFOSale10,568$17.76$187.7KForm 4
May 17, 2024Galloway Heath HEVP,General Counsel & CorpSecySale2,052$19.06$39.1KForm 4

All 54 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Coliseum Capital Management, LLC13,100,807$44.8M3.9%No change
BlackRock, Inc.5,504,102$18.8M0.0%+268,802
Bank Of America Corp /de/3,775,525$12.9M0.0%+368,450
Vanguard Capital Management LLC3,087,931$10.6M0.0%−194,243
D. E. Shaw & Co., Inc.3,081,407$10.5M0.0%−230,194
Charles Schwab Investment Management Inc2,888,058$9.9M0.0%−747,468
Invenomic Capital Management LP2,812,474$9.6M0.6%−556,501
Marshall Wace, Llp2,582,579$8.8M0.0%+821,575
Paradigm Capital Management Inc/ny2,536,699$8.7M0.2%+750,299
Vanguard Portfolio Management LLC2,030,956$6.9M0.0%−620,196
Dana Investment Advisors, Inc.1,944,607$6.7M0.2%+459,510
Geode Capital Management, LLC1,873,127$6.4M0.0%+37,217
Dimensional Fund Advisors LP1,640,163$5.6M0.0%−966,457
State Street Corp1,601,162$5.5M0.0%−28,794
Connor, Clark & Lunn Investment Management Ltd.1,288,787$4.4M0.0%−91,941
Aqr Capital Management LLC1,067,324$3.7M0.0%+335,103
Goldman Sachs Group Inc854,730$2.9M0.0%−86,443
Two Sigma Investments, LP718,550$2.5M0.0%−482,719
Northern Trust Corp581,804$2.0M0.0%−19,157
Wolverine Asset Management LLC568,084$1.9M0.1%−127,331
Tudor Investment Corp Et Al567,250$1.9M0.0%+351,698
Vanguard Global Advisers, LLC509,492$1.7M0.0%+86,818
Vanguard Fiduciary Trust Co487,109$1.7M0.0%+19,012
BW Gestao de Investimentos Ltda.423,091$1.4M0.0%New
Citadel Advisors LLC386,526$1.3M0.0%+151,387

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Owens & Minor is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARACCENDRA HEALTH INC/VA/2
  • CIK0000075252
  • Employer ID (EIN)54-170184317
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inVirginia17
  • Fiscal year endsDecember 312
  • Industry code (SIC)5047 Wholesale-Medical, Dental & Hospital Equipment & Supplies2
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance2
  • Business address4435 Waterfront Drive, Suite 300, Glen Allen, VA2
  • Phone80427743042
  • Shares outstanding76,904,704 as of Jun 30, 202615
  • Public float$677.5M as of Jun 30, 202517
  • AuditorKPMG, LLP, Richmond, VA PCAOB ID 185; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceJan 6, 19942
  • Filings3,102 in all: 4 (2,062), 8-K (303), SC 13G/A (125), 10-Q (98), 4/A (76), 3 (58), 5 (39), SC 13G (33)2
    All 52 form types

    144 (32), DEF 14A (32), 10-K (29), UPLOAD (25), CORRESP (22), DEFA14A (20), 11-K (16), S-8 (16), ARS (14), 8-K/A (12), SCHEDULE 13G/A (11), SD (8), S-3/A (6), 10-Q/A (5), 424B3 (5), S-8/A (5), 10-K405 (4), S-3 (4), SCHEDULE 13G (4), 424B2 (3), 424B4 (3), S-3ASR (3), S-8 POS (3), 10-K/A (2), 8-A12B (2), EFFECT (2), FWP (2), S-4 (2), 10-K405/A (1), 15-12B (1), 15-12G (1), 15-15D (1), 3/A (1), 424B5 (1), 8-B12B (1), 8-B12B/A (1), 8A12BT (1), CERTNYS (1), NT 10-K (1), POS AM (1), PRE 14A (1), S-4/A (1), SC 13D/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Feb 20, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 2, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $2 par valueACHNew York Stock Exchange

From the cover page of the 10-K filed Feb 20, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Owens & Minor names in Item 1A of its 10-K filed Feb 20, 2026: 38 risks under these headings, as written.17

  • Index to Risk Factors
  • Forward-Looking Statements and Risk Factors Summary
  • Risks Related to the Sale of our Products & Healthcare Services Business
  • Litigation & Regulatory Risks
  • We have concentration in and dependence on certain Payors.
  • Our failure to establish and maintain relationships with hospital and physician referral sources may cause our revenue to decline.
  • Possible changes in customer and product mix could have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.
  • Our business is dependent on certain significant suppliers.
  • Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure.
  • The recent termination of certain contracts commercial Payor could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.
  • A determination from the Centers for Medicare and Medicaid Services (CMS) would reduce reimbursement qualification for non-invasive ventilation products, which could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.
  • Our ability to attract and retain talented and qualified teammates is critical to our success and competitiveness.
The other 29 risks
  • Our inability to adequately integrate acquisitions could have a material adverse effect on our operations.
  • Our operations involve the storage, transportation and provision of compressed and liquid oxygen, which carries an inherent risk of rupture or other accidents with the potential to cause substantial loss.
  • Our goodwill may become further impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
  • We have sold our P&HS business, and there may be negative impacts on our financial condition, results of operations, cash flows, capital resources and liquidity.
  • In connection with the sale of the P&HS business, we are required to provide certain transitional services which may divert management’s attention and harm our business.
  • In connection with the sale of the P&HS business, we are receiving certain transitional services and are dependent on the successful execution of these services by a third party.
  • Certain contracts used in our business were transferred or may need to be transferred or replaced in connection with the sale of the P&HS business and any failure to obtain such replacement contracts could increase our expenses or otherwise adversely affect our results of operations.
  • The sale of certain assets associated with the P&HS business could negatively impact our business, and retained liabilities from businesses or assets that we have sold could adversely affect our financial results.
  • We face increasing competition, accelerating pricing pressure and changes in technology.
  • Uncertainty about current and future economic conditions and other adverse changes in general political conditions may adversely affect demand for our products and services and collectability of our accounts receivable.
  • Changing conditions in the U.S. healthcare industry may impact our results of operations and cash flows.
  • We are subject to stringent regulatory and licensing requirements, and we have been, are and in the future could become the subject of federal and state investigations and compliance reviews.
  • We must obtain clearance or approval from appropriate regulatory authorities prior to consummating transactions of certain healthcare related businesses.
  • Our failure to comply with regulatory requirements or receive regulatory clearances or approvals for our medical gas facilities, products or operations could adversely affect our business.
  • Our business may be adversely affected if we are unable to adequately establish, maintain, protect and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of such rights.
  • We may become subject to litigation, investigations, claims and other legal proceedings brought by regulatory agencies, third parties, or individuals.
  • We could be subject to adverse changes in the tax laws or challenges to our tax positions.
  • Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
  • Our aspirations, goals and disclosures related to ESG matters expose us to numerous risks, including risks to our reputation and stock price.
  • Our amended and restated bylaws designate the U.S. District Court for the Eastern District of Virginia as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
  • We may not be able to refinance, extend or repay our substantial indebtedness which would have a material adverse effect on our financial condition.
  • We may not be able to generate sufficient cash to service our debt and other obligations.
  • Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
  • Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly.
  • Despite current indebtedness levels, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial, which could further exacerbate the risks described herein.
  • Our continued success is substantially dependent on positive perceptions of our reputation.
  • We are subject to risks related to public health crises, future outbreaks of health crises or other adverse public health developments.
  • The market price for our common stock and debt have been, and may continue to be, highly volatile.
  • We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.

Legal proceedings

Certain legal proceedings in which we are involved are discussed in Note 15, “Commitments, Contingent Liabilities, and Legal Proceedings”, in the Notes to Consolidated Financial Statements in this Annual Report.

We are party to various legal claims that are ordinary and incidental to our business, including ones related to commercial disputes, employment, workers’ compensation, product liability, regulatory and other matters. We maintain insurance coverage for cybersecurity, employment, product liability, workers’ compensation and other personal injury litigation matters, subject to policy limits, applicable deductibles and insurer solvency. From time to time, we establish estimated liabilities based upon periodic assessment of the potential outcomes of pending matters.

Based on current knowledge and the advice of counsel, we believe that the liability recorded on the consolidated balance sheet as of December 31, 2025 for currently pending matters considered probable of loss, is sufficient. In addition, we believe that other currently pending matters are not reasonably possible to result in a material loss, as payment of the amounts claimed is remote, the claims are immaterial, individually and in the aggregate, or the claims are expected to be adequately covered by insurance, subject to policy limits, applicable deductibles, exclusions, and insurer solvency.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
  118. 118
    SEC EDGAROther events
  119. 119
  120. 120
  121. 121
  122. 122
  123. 123
  124. 124
  125. 125
  126. 126
  127. 127
  128. 128
  129. 129
  130. 130
  131. 131
  132. 132
  133. 133
  134. 134
  135. 135
  136. 136
  137. 137
  138. 138
  139. 139